Earnings Summary

ChemoCentryx Inc’s revenue jumped 592.35% since last year same period to $11.76Mn in the Q2 2022. On a quarterly growth basis, ChemoCentryx Inc has generated 115.48% jump in its revenue since last 3-months.

ChemoCentryx Inc’s net profit jumped 19.28% since last year same period to $-31.65Mn in the Q2 2022. On a quarterly growth basis, ChemoCentryx Inc has generated 18.02% jump in its net profits since last 3-months.

ChemoCentryx Inc’s net profit margin jumped 88.34% since last year same period to -269.07% in the Q2 2022. On a quarterly growth basis, ChemoCentryx Inc has generated 61.95% jump in its net profit margins since last 3-months.

ChemoCentryx Inc’s earning per share (EPS) estimates for the current quarter stand at -0.37 - a 11.94% jump from last quarter’s estimates.

ChemoCentryx Inc’s earning per share (EPS) estimates for the current year stand at -0.37.

ChemoCentryx Inc’s earning per share (EPS) jumped 21.43% since last year same period to -0.44 in the Q2 2022. This indicates that the ChemoCentryx Inc has generated 21.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ChemoCentryx Inc’s return on assets (ROA) stands at -0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ChemoCentryx Inc’s return on equity (ROE) stands at -0.47.